Health Care [ 8/12 ] | Biotechnology [ 34/74 ]
NASDAQ | Common Stock
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States.
The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA).
It also provides QALSODY for the treatment of Amyotrophic Lateral Sclerosis (ALS); TEGSEDI for the treatment of ATTRv-PN in adults; and WAYLIVRA for treatment for FCS and familial partial lipodystrophy.
It also develops products under Phase 3 clinical trials, such as Olezarsen for patients with hypertriglyceridemia (SHTG) and cardiovascular disease (CVD); Donidalorsen for patients with hereditary angioedema; and Zilganerse, a potential treatment for people with genetically confirmed Alexander disease, as well as ION582 that has completed Phase 2 clinical trial for the potential treatment of AS, a rare genetic neurological disease.
In addition, the company develops Eplontersen to degrade mutant and wild-type TTR mRNA through binding to the TTR mRNA; Pelacarsen to inhibit the production of apolipoprotein(a) in the liver to offer a direct approach for reducing lipoprotein(a); Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus; Sefaxersen to reduce the production of complement factor B and lower activation of the alternative complement pathway; and Ulefnersen to reduce the production of the fused in sarcoma, as well as other mid-stage pipeline investigational medicines.
It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with GSK, AstraZeneca, Novartis, and Roche, as well as with Metagenomi.
The company was incorporated in 1989 and is headquartered in Carlsbad, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 19, 25 | -0.43 Decreased by -617.33% | -0.84 Increased by +49.03% |
| Nov 6, 24 | -0.95 Increased by +7.77% | -1.16 Increased by +18.10% |
| Aug 1, 24 | -0.45 Increased by +25.00% | -0.92 Increased by +51.09% |
| May 7, 24 | -0.98 Decreased by -12.64% | -1.05 Increased by +6.67% |
| Feb 21, 24 | -0.06 Increased by +95.59% | -0.83 Increased by +92.77% |
| Nov 2, 23 | -1.03 Decreased by -212.12% | -1.04 Increased by +0.96% |
| Aug 9, 23 | -0.60 Increased by +18.92% | -0.90 Increased by +33.33% |
| May 3, 23 | -0.87 Decreased by -89.13% | -0.91 Increased by +4.40% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 226.58 M Decreased by -30.18% | -104.35 M Decreased by -1.03 K% | Decreased by -46.05% Decreased by -1.51 K% |
| Sep 30, 24 | 134.00 M Decreased by -6.94% | -140.48 M Increased by +4.44% | Decreased by -104.84% Decreased by -2.70% |
| Jun 30, 24 | 225.25 M Increased by +19.81% | -66.27 M Increased by +22.04% | Decreased by -29.42% Increased by +34.93% |
| Mar 31, 24 | 119.50 M Decreased by -8.78% | -142.80 M Decreased by -15.16% | Decreased by -119.50% Decreased by -26.25% |
| Dec 31, 23 | 324.50 M Increased by +113.49% | -9.26 M Increased by +82.19% | Decreased by -2.85% Increased by +91.66% |
| Sep 30, 23 | 144.00 M Decreased by -9.87% | -147.00 M Decreased by -212.82% | Decreased by -102.08% Decreased by -247.07% |
| Jun 30, 23 | 188.00 M Increased by +40.52% | -85.00 M Increased by +19.15% | Decreased by -45.21% Increased by +42.46% |
| Mar 31, 23 | 131.00 M Decreased by -7.69% | -124.00 M Decreased by -90.29% | Decreased by -94.66% Decreased by -106.15% |